[Menu] [Previous] [Next]

TUTORIAL: Clinical PET - Cardiology

Use the "Menu" button to jump to the Let's Play PET Main Menu or click on the Next and Previous buttons to proceed sequentially through the topics and tutorials. Or, you can return to the Department of Molecular and Medical Pharmacology's Home Page.

Contents:
Topics:
  • Cardiac Scan Evaluation
  • Dietary Effects on FDG Metabolism
  • Parametric Imaging
  • Polar Maps
  • Single Vessel Disease
  • Double Vessel Disease
  • Myocardial Viability - Mismatch
  • Myocardial Viability - Match
  • Ischemic Dilated Cardiomyopathy
  • Idiopathic Dilated Cardiomyopathy

  • Double Vessel Disease


    Click on image above to view full-size image.

    This study represents a case where there is disease in two cardiac blood vessels. The flow images on the left show decreased flow in the anterior and septal regions. The FDG metabolic images on the right show low metabolic activity in the corresponding regions.


    Click on image above to view full-size image.

    The polar maps above were obtained from the previous images. The flow polar map shows a clear deficit involving the anterior and septal regions of the myocardium. The FDG metabolic polar map shows hypometabolism in the corresponding regions (a match). Note that both the LAD and RCA vessels are involved in this case. The LCX territories seem well perfused. This is an example of double-vessel disease, with little viable tissue remaining (suggested by the low FDG metabolism in the poorly perfused regions).


    Click on image above to view full-size image.

    Seen here are the flow-minus-metabolism polar map from the previous study (left image) and the flow-minus-metabolism polar map normalized to a database of normals (right image). Note that there is little evidence of mismatch (red color), indicating both decreased perfusion and decreased metabolism (a match). Thus little viable tissue is apparent in the supply territories of the LAD and RCA vessels.

    Credits

    Material for this section was kindly provided by:

    Johannes Czernin, M.D.
    Dept. of Molecular and Medical Pharmacology
    UCLA School of Medicine

    Heinrich R. Schelbert, M.D., Ph.D.
    Dept. of Molecular and Medical Pharmacology
    UCLA School of Medicine

    Return to Top of Tutorial


    [Menu] [Previous] [Next]